<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117634</url>
  </required_header>
  <id_info>
    <org_study_id>R1448/31/2017</org_study_id>
    <nct_id>NCT03117634</nct_id>
  </id_info>
  <brief_title>An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen</brief_title>
  <official_title>An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore National Eye Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Singapore National Eye Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polypoidal choroidal neovasculopathy (PCV) is a subtype of wet age related macula
      degeneration (AMD) occuring more commonly in the Asian population. Besides the phenotypic
      differences, PCV is thought to have a lesser response to anti VEGF therapy which is the
      mainstay of treatment for other typical wet AMD. Recent trial data suggest that a combination
      with photodynamic therapy may help in the visual and anatomical outcome of PCV, and emerging
      evidence shows favourable outcomes the newer anti VEGF agent, aflibercept 2mg monotherapy.
      These trials however, have assessed aflibercept in a strict 2mg every 8 weekly regime.

      In the clinical setting, a significant an unmet need in the management of PCV is a tailored
      treatment regime. Here we propose a treatment regimen based on disease activity for PCV with
      aflibercept mono therapy. A limitation of the 2q8 regime is that it is fixed and does not
      vary regardless of polyp closure or anatomical outcome at the first time point of assessment
      (month 3). We hypothesize that after the initial 3 monthly injections of aflibercept, about
      50% of PCV will close and become quiescent, and in the remaining 50%, a further 3 monthly
      injections will increase overall polyp closure rate. After a loadings phase of either 3 or 6
      months, all eyes will start on a treat and extend regime (T&amp;E), with a minimum period of 8
      weeks and a maximum of 12 weeks between treatments with 2 week increments if PCV remains
      quiescent. The proposed study aims to evaluate the efficacy of a modified treat and extend
      regime based on disease activity with aflibercept monotherapy for PCV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Age related macular degeneration (AMD) is one of the leading causes of blindness worldwide.
      In its exudative or wet form, choroidal neovascularization (CNV) causes an exudative
      maculopathy resulting in sudden loss of vision with severe effects on patients' quality of
      life.1,2 Intra vitreal injections of anti-vascular endothelial growth factor agents
      (anti-VEGF) agents have become the mainstay of treatment for AMD CNV and have been shown to
      have favorable outcomes in most AMD CNV subtypes.3,4 In the Asian population however, a
      particular subtype called polypoidal choroidal vasculopathy (PCV), which affects about 50% of
      exudative maculopathy, has been shown to have less favorable response to anti-VEGF
      therapy.5,6 The EVEREST trial, a randomized controlled trial which compares the efficacy of
      photodynamic therapy (PDT) with or without ranibizumab for treatment of PCV showed that PDT
      with or without anti VEGF improved polyp closure rate on angiographic assessment but this
      trial did not take into account vision as a primary end point.7 PDT appears work through its
      effects on choroidal vasculature, hence making it relevant to PCV which is increasingly
      thought to be a condition on the pachychoroid spectrum.8 PDT however, as a treatment modality
      presents several disadvantages. Firstly, PCV often presents as a widely distributed lesion,
      making it difficult to treat, with a single beam of PDT. Secondly, PDT is limited in its
      ability to treat lesions in the peripapillary area as there is risk of damage to the optic
      nerve. Thirdly, features commonly associated with PCV such as a large pigment epithelial
      detachment (PED) or extensive submacular hemorrhages are not usually suitable for PDT.
      Fourthly, there is a risk of long-term choroidal atrophy especially if repeated treatments
      are administered.8,9

      There is emerging evidence for the use of aflibercept monotherapy in PCV. Reports range from
      small case series and retrospective studies to larger prospective studies. Recent data from
      the PLANET study showed that monotherapy of aflibercept resulted in similar letter gains in
      visual acuity as compared to combination treatment with PDT at 1 year. Polyp closure rate was
      also similar between the two groups at 38.9% with monotherapy and 44.8% with combination
      therapy. The VAULT and APOLLO studies suggest vision and anatomical improvements with 66-72%
      polyp closure in 1 year.10 These trials however, use a fixed dosing regimen (3 monthly
      loading doses of 2mg aflibercept followed by fixed dosing every 8 weeks (2q8) totaling 7
      injections in 1 year). In addition to resolution of subretinal fluid, recent studies using
      the novel OCT-angiography (OCT-A) to evaluate choroidal vasculature suggests re-modelling of
      choroidal vasculature may also be an important therapeutic effect. We reported more prominent
      reduction in choroidal vessel calibre after combination treatment with PDT and bevacizumab
      compared to bevacizumab monotherapy. The effect of Aflibercept on choroidal vasculature has
      been less well studied. Some evidence however, suggested aflibercept may have more profound
      effect on choroidal vasculature with the reducing choroidal thickness than ranibizumab or
      bevacizumab.

      A significant unmet need in the management of PCV with anti VEGF monotherapy is a practical
      way of treating patients in the real world setting that maximizes efficacy with minimal
      number of visits and injections. Clinical trial regimes follow a rigid treatment algorithm
      that aim to maximize response. In the clinical setting, these regimes are impractical in
      &quot;real world&quot; patients. Regular intensive course of treatment involves lengthy visits which
      include consultation time, clinical examination, retinal imaging, and often an intra vitreal
      injection. In clinical practice this often result in treatment fatigue and in a co-payment
      healthcare environment in Singapore, may also result in significant financial burden to the
      patient and society.

      While aflibercept affords an 8 weekly treatment regime which is better than other monthly
      anti VEGF therapy regimes, trial regimes still do not take into account individual patients'
      disease patterns. This study aims to take disease activity into account to tailor treatment
      regimes specific for patients. In addition, it aims to provide insight into the outcomes of
      patients on a more clinically relevant treat and extend (T&amp;E) regime which changes the
      treatment tempo in relation to disease activity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, 2-arm, Non-inferiority, interventional study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>12 months</time_frame>
    <description>LogMAR reading of BCVA after interventions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Closure rate</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>polyp closure rate as seen on Indocyanine green angiography (ICGA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of injections</measure>
    <time_frame>12 months</time_frame>
    <description>number of aflibercept injections administered</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <condition>Polypoidal Choroidal Vasculopathy</condition>
  <arm_group>
    <arm_group_label>Fixed dosing group (2Q8)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fixed Dosing with Aflibercept 2mg will be administered at a fixed regime at 8 week intervals through to week 52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat and Extend group (T&amp;E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reassessment at week 12 (month 3) by repeat examination for disease activity by OCT and ICGA. Subsequent treatment regime of Treat and Extend with Aflibercept 2mg will depend on disease activity at this point.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treat and Extend with Aflibercept 2mg</intervention_name>
    <description>Drug treatment regime which allows extension of treatment interval based on disease activity</description>
    <arm_group_label>Treat and Extend group (T&amp;E)</arm_group_label>
    <other_name>T&amp;E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed Dosing with Aflibercept 2mg</intervention_name>
    <description>Fixed 8 weekly dosing regime throughout the study duration</description>
    <arm_group_label>Fixed dosing group (2Q8)</arm_group_label>
    <other_name>2Q8</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Participant

          1. Male or female study participants, age &gt;=45 years of age at the time of informed
             consent.

          2. Best corrected ETDRS visual acuity score &lt;= 78 (ie 20/32 or worse)

          3. Diagnosis of PCV based on ICGA

               1. Presence of intra retinal or subretinal fluid/blood at the fovea as seen on OCT

               2. Treatment na√Øve

          4. Media clarity, pupillary dilation and individual cooperation sufficient for study
             procedure including fundus photography.

          5. Able and willing to provide informed consent.

        1.2. Exclusion Criteria Participant

          1. Medical condition that, in the opinion of the investigator, would preclude
             participation in the study (e.g.unstable medical status including blood pressure,
             cardiovascular disease, and glycemic control).

          2. Participation in an investigational trial within 30 days of enrolment which involves
             treatment with unapproved investigational drug

          3. Known allergy to any component of the study drug.

          4. Blood pressure &gt; 180/110 (systolic above 180 OR diastolic above 110 on repeated
             measurements). If blood pressure is brought below 180/110 by anti-hypertensive
             treatment, individual can become eligible.

          5. Myocardial infarction, other acute cardiac event requiring hospitalization, stroke,
             transient ischemic attack, or treatment for acute congestive heart failure within 4
             months prior to randomization.

          6. Systemic anti-VEGF or pro-VEGF treatment within four months prior to randomization or
             anticipated use during the study.

        Study Eye

          1. Eye with intra retinal or subretinal fluid due to other causes than PCV

          2. An ocular condition is present (other than PCV) that, in the opinion of the
             investigator, might affect intra or sub retinal fluid or alter visual acuity during
             the course of the study (e.g., diabetic macula edema (DME), vein occlusion, uveitis or
             other ocular inflammatory disease, neovascular glaucoma, etc.)

          3. Substantial cataract that, in the opinion of the investigator, is likely to be
             decreasing visual acuity by more than three lines (i.e., cataract would be reducing
             acuity to worse than 20/40 if eye was otherwise normal).

          4. Any intraocular surgery within 3 months of enrollment

          5. Treatment with intra vitreal corticosteroids

          6. History of retinal detachment or surgery for retinal detachment

          7. History of vitrectomy

          8. History of macular hole

          9. Evidence of vitreomacular traction that may preclude resolution of macular edema &gt; 4
             disc areas of intra/sub retinal hemorrhage

         10. Aphakia

         11. Exam evidence of external ocular infection, including conjunctivitis, chalazion, or
             significant blepharitis

        Other Eye

          1. Active intraocular inflammation

          2. History of uveitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gemmy Cheung</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNEC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SNEC</last_name>
    <phone>6322 4500</phone>
    <email>kelvin.teo.y.c@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Singapore National Eye Centre</name>
      <address>
        <city>Singapore</city>
        <state>Singpore</state>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemmy Cheung, MBBS</last_name>
      <phone>6322 4500</phone>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti vegf</keyword>
  <keyword>aflibercept</keyword>
  <keyword>treat and extend</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

